{"id":"hepatitis-b-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain, redness, or swelling"},{"rate":"1-6","effect":"Fever"},{"rate":"1-5","effect":"Fatigue"},{"rate":"1-5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_dailymed":{"setId":"3ed8472a-c6eb-4076-9d66-025ede589e3d","title":"VAXELIS (DIPHTHERIA AND TETANUS TOXOIDS AND ACELLULAR PERTUSSIS, INACTIVATED POLIOVIRUS, HAEMOPHILUS B CONJUGATE AND HEPATITIS B VACCINE) INJECTION, SUSPENSION [MSP VACCINE COMPANY]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains hepatitis B surface antigen (HBsAg), typically produced via recombinant DNA technology, which triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HBs) and memory B cells that recognize and neutralize the virus upon exposure, preventing infection and chronic disease.","oneSentence":"The Hepatitis B vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:31.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B virus infection in infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT00001971","phase":"","title":"Evaluation of Patients With Liver Disease","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1992-05-27","conditions":"Hepatitis D, Hepatitis C, Hepatitis B","enrollment":8050},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":"HEPATITIS B CHRONIC, Hepatitis D, Periodontitis","enrollment":25},{"nctId":"NCT00001352","phase":"","title":"Fungal Infection Susceptibility","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-04-01","conditions":"Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis","enrollment":800},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT06544863","phase":"","title":"Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-19","conditions":"Cirrhosis","enrollment":3000},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT03394053","phase":"","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-30","conditions":"Primary Immunodeficiency Disorders","enrollment":2500},{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":"Chronic Hepatitis B","enrollment":45},{"nctId":"NCT06092333","phase":"PHASE2","title":"VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2025-01-31","conditions":"Chronic Hepatitis B","enrollment":50},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07481032","phase":"NA","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-04-01","conditions":"Cirrhosis, Liver, Hepatocellular Carcinoma (HCC), HEPATITIS B CHRONIC","enrollment":1034},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT07471217","phase":"PHASE1","title":"[¹⁴C] Hydronidone Mass Balance Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-04-30","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":8},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT00004850","phase":"","title":"Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1991-03-15","conditions":"Hepatitis C, Hepatitis B","enrollment":805},{"nctId":"NCT07450651","phase":"","title":"Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-02","conditions":"Hepatitis B Virus Related Cirrhosis, Portal Hypertension Related to Cirrhosis, Esophagogastric Varices","enrollment":150},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT03419481","phase":"PHASE2","title":"Pembrolizumab in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2018-04-30","conditions":"HCC","enrollment":30},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT05621304","phase":"","title":"Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-01-03","conditions":"Chronic Hepatitis B Virus (Hbv)","enrollment":274},{"nctId":"NCT07342881","phase":"PHASE1","title":"Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Infection","enrollment":30},{"nctId":"NCT06779058","phase":"","title":"MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2025-01-01","conditions":"Chronic Hepatitis B, Liver Fibrosis","enrollment":600},{"nctId":"NCT04357600","phase":"PHASE1, PHASE2","title":"Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2018-05-17","conditions":"Liver Cirrhoses","enrollment":12},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":"Chronic Hepatitis b, Hepatitis B Reactivation","enrollment":260},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":"HIV Infections, Drug Use, Opioid Use","enrollment":447},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT07236268","phase":"","title":"Prevalence of HIV and Sexually Transmitted Infections in Migrant Communities in Slovakia","status":"COMPLETED","sponsor":"Comenius University","startDate":"2023-03-15","conditions":"STIs, HIV, Rapid Detection","enrollment":660},{"nctId":"NCT07417553","phase":"PHASE2","title":"A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-03-15","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":150},{"nctId":"NCT07413549","phase":"PHASE1, PHASE2","title":"Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis","status":"RECRUITING","sponsor":"Beijing Tuohua Weiye Biotechnology Co., Ltd.","startDate":"2025-02-25","conditions":"Decompensated Hepatitis B Cirrhosis","enrollment":76},{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT05390424","phase":"NA","title":"Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2022-12-02","conditions":"Hepatitis B, Hepatitis C, AIDS","enrollment":500},{"nctId":"NCT07394309","phase":"PHASE1","title":"Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-15","conditions":"Liver Fibrosis","enrollment":30},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05612581","phase":"PHASE1, PHASE2","title":"A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-05-10","conditions":"Hepatitis B, Chronic","enrollment":33},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":"Chronic Hepatitis B Infection","enrollment":200},{"nctId":"NCT07388979","phase":"","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","status":"NOT_YET_RECRUITING","sponsor":"Gardiens de Vies","startDate":"2026-03-01","conditions":"HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus), Hepatitis C Virus (HCV)","enrollment":7500},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06497504","phase":"PHASE2","title":"Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-17","conditions":"Hepatitis B","enrollment":157},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06082336","phase":"NA","title":"Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2024-09-16","conditions":"Combined Point of Care Diagnostic of HIV, HBV and HCV","enrollment":252},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07170748","phase":"","title":"Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2025-07-29","conditions":"Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV","enrollment":2950},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":"Hepatitis b Virus, Hepatitis B","enrollment":37},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT01651403","phase":"PHASE3","title":"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":"Chronic Hepatitis b, NAFLD, Cirrhosis","enrollment":106},{"nctId":"NCT07200193","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"nChroma Bio","startDate":"2025-12-22","conditions":"Chronic Hepaititis B","enrollment":66},{"nctId":"NCT07370207","phase":"PHASE2","title":"Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region","status":"NOT_YET_RECRUITING","sponsor":"AusperBio Therapeutics Inc.","startDate":"2026-02-02","conditions":"Hepatitis B, Chronic","enrollment":84},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT05770895","phase":"PHASE1","title":"Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-04-03","conditions":"Chronic Hepatitis B","enrollment":83},{"nctId":"NCT07364448","phase":"PHASE2","title":"A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":200},{"nctId":"NCT07090759","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2025-07-24","conditions":"Chronic Hepatitis b","enrollment":526},{"nctId":"NCT01298037","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2011-02-01","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT01796457","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2013-03","conditions":"Hepatitis B","enrollment":40},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":"Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder])","enrollment":1800},{"nctId":"NCT03149627","phase":"","title":"Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-07","conditions":"HBV, Alcoholic Hepatitis, Liver Fibroses","enrollment":5003},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT04294433","phase":"PHASE4","title":"Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children","status":"COMPLETED","sponsor":"Laval University","startDate":"2018-06-11","conditions":"Hepatitis B","enrollment":431},{"nctId":"NCT07317687","phase":"","title":"Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","status":"NOT_YET_RECRUITING","sponsor":"West Virginia University","startDate":"2026-01","conditions":"HIV Testing, HEPATITIS C (HCV), Syphilis","enrollment":200},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT07346508","phase":"NA","title":"Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol","status":"NOT_YET_RECRUITING","sponsor":"KC Care Health Center","startDate":"2026-04-01","conditions":"HIV (Human Immunodeficiency Virus)","enrollment":250},{"nctId":"NCT07343778","phase":"PHASE3","title":"A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-20","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":300},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":"Chronic Hepatitis B","enrollment":209},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT07328711","phase":"EARLY_PHASE1","title":"Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Chronic Hepaititis B","enrollment":132},{"nctId":"NCT06624176","phase":"NA","title":"ShotBlocker During Intramuscular Injection Randomized Control Trial","status":"RECRUITING","sponsor":"Lauren Fortier","startDate":"2024-01-10","conditions":"Neonatal Pain","enrollment":200},{"nctId":"NCT06671093","phase":"PHASE1","title":"Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Tune Therapeutics, Inc.","startDate":"2024-11-29","conditions":"Chronic Hep B, Chronic Hepatitis b, Chronic Hepatitis","enrollment":36},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT07307586","phase":"PHASE3","title":"A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Zhigang Ren","startDate":"2025-09-01","conditions":"Chronic Hepatitis B, Azvudine","enrollment":120},{"nctId":"NCT06993480","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","status":"RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-06-18","conditions":"Chronic Hepatitis B","enrollment":30},{"nctId":"NCT02349126","phase":"PHASE2","title":"Study of ARC-520 in Patient With Chronic Hepatitis B Virus","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT06347588","phase":"","title":"Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-06-06","conditions":"Occult Hepatitis B Infection in Cancer Patients","enrollment":60},{"nctId":"NCT07246889","phase":"PHASE3","title":"Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-12","conditions":"Chronic Hepatitis B","enrollment":577},{"nctId":"NCT06901362","phase":"","title":"Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"Healthy, Healthy Adult","enrollment":401},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT05127187","phase":"NA","title":"Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-02-08","conditions":"HIV Infections, Hepatitis C, Hepatitis B","enrollment":350},{"nctId":"NCT06494579","phase":"PHASE1, PHASE2","title":"Lamivudine for Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2024-09-26","conditions":"Relapsed/Refractory Solid Tumors","enrollment":12},{"nctId":"NCT07085377","phase":"NA","title":"Autonomous Methadone Delivery System by Nurses","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-08","conditions":"Opioid Use Disorder (OUD), Addictology","enrollment":182},{"nctId":"NCT07282249","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2025-12-31","conditions":"Chronic hepatitisB","enrollment":630},{"nctId":"NCT01198860","phase":"","title":"Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B","status":"APPROVED_FOR_MARKETING","sponsor":"Nguyen Thi Trieu, MD","startDate":"","conditions":"CHRONIC HEPATITIS B","enrollment":""},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":"HIV, HBV (Hepatitis B Virus), HCV","enrollment":50},{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":"Vaccine Reaction","enrollment":101},{"nctId":"NCT05630807","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-07","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":981},{"nctId":"NCT06909188","phase":"","title":"The Study of Association of Helicobacter Infections in Biliary Tract Cancers","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-03-31","conditions":"Biliary Tract Cancer","enrollment":250},{"nctId":"NCT05630820","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-06","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":857}],"_emaApprovals":[],"_faersSignals":[{"count":58,"reaction":"FATIGUE"},{"count":46,"reaction":"DYSPNOEA"},{"count":45,"reaction":"DIARRHOEA"},{"count":41,"reaction":"NAUSEA"},{"count":40,"reaction":"HEADACHE"},{"count":39,"reaction":"ARTHRALGIA"},{"count":36,"reaction":"PYREXIA"},{"count":35,"reaction":"VOMITING"},{"count":34,"reaction":"PAIN"},{"count":33,"reaction":"DIZZINESS"}],"_approvalHistory":[],"publicationCount":5019,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HB-Vax-II","Hep B vaccine","Euvax B (Sonafi)","Engerix-B","HBVAXPRO"],"phase":"marketed","status":"active","brandName":"Hepatitis B Vaccine","genericName":"Hepatitis B Vaccine","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The Hepatitis B vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in infants, children, and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}